IntoCell, Inc. Logo

IntoCell, Inc.

Develops and licenses proprietary ADC platform technologies for cancer & immune therapies.

287840 | KO

Overview

Corporate Details

ISIN(s):
KR7287840003
LEI:
Country:
South Korea
Address:
대전광역시 대덕구 신일동로 101, 대전광역시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

IntoCell, Inc. is a biotechnology company specializing in the research and development of novel biopharmaceuticals. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) platform technologies, including its OHPAS™ linker and Payload Modification Technology. IntoCell leverages these platforms to develop targeted therapies for cancer and immunological disorders. The company's business model is centered on the commercialization and transfer of its innovative ADC technologies to global partners in the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (ITC6146RO의 한국 MFDS 제1상 임상시험계획 승인신청)
Korean 8.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 758.7 KB
2025-07-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.3 KB
2025-07-09 00:00
Regulatory News Service
투자판단관련주요경영사항 (ADC 플랫폼 기술에 대한 실시권 계약 해지)
Korean 6.6 KB
2025-07-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.8 KB
2025-06-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 63.6 KB
2025-05-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 73.6 KB
2025-05-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 185.8 KB
2025-05-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 65.6 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB

Automate Your Workflow. Get a real-time feed of all IntoCell, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IntoCell, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IntoCell, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.